U.S. Healthtech Stock News

In recent weeks, Kraft Heinz’s previously undisclosed merger talks with Unilever’s food business ended without a deal, while the company pushed ahead with a five‑year global partnership as the NFL’s first-ever global condiment partner and launched higher‑protein PowerMac alongside new factory investments and international plant closures. Together, these moves highlight Kraft Heinz’s effort to refresh its portfolio, deepen brand visibility through sports tie‑ins, and rebalance its global...

Why Comstock Resources Stock Is Back in Focus Comstock Resources (CRK) is drawing fresh attention after its Western Haynesville position was selected to host the Texas Natural Gas Fired Power Generation Hub, which is tied to Japan's reported US$550 billion U.S. investment commitment. The project will be developed near Comstock's Western Haynesville natural gas operations in Anderson County, Texas, and involves collaboration with NextEra Energy and joint U.S. and Japanese ownership under the...

VICI Properties Inc. recently expanded its long-term relationship with Cain and Eldridge Industries by providing a US$1.50 billion mezzanine loan behind a US$2.80 billion senior loan led by J.P. Morgan to help finance the One Beverly Hills luxury mixed-use development. This financing not only deepens VICI’s role in a high-profile Beverly Hills project anchored by Aman Beverly Hills and a refurbished Beverly Hilton, it also lays groundwork for an Experiential Cross-Capital Venture that could...

With no single headline event driving attention to Bank of New York Mellon Corporation (BK) today, investors are focusing on how its recent share performance and profitability metrics compare with its sizeable US$80.1b market value. See our latest analysis for Bank of New York Mellon. BNY's recent 1.3% one day share price return, alongside a broadly flat year to date move, contrasts with a 1 year total shareholder return of 41.2% and a 3 year total shareholder return of 191.8%. This suggests...

If you are wondering whether BOK Financial at around US$126.55 is offering good value today, you are not alone. This article focuses squarely on what that price might mean for long term investors. The stock has returned 1.4% over the last 7 days, 6.6% year to date and 23.8% over the past year, although the last 30 days have seen a 5.6% decline that may have changed how some investors think about its risk and return trade off. Recent coverage has focused on how BOK Financial fits into the...

The U.S. government has launched a multi trillion dollar investment consortium focused on critical semiconductor supply chains and materials. The program includes initial government funding aimed at domestic and allied chip manufacturing and supporting infrastructure. This policy move creates a potential tailwind for process control and inspection providers such as KLA (NasdaqGS:KLAC). KLA enters this policy shift with strong share price momentum, with NasdaqGS:KLAC up 5.7% over the past...

Customers Bancorp (CUBI) has drawn attention after recent trading left the stock with a return of about 1% over the past day, while showing declines over the past month and past 3 months. See our latest analysis for Customers Bancorp. That short term weakness, with a 30 day share price return of 6.63% and a 90 day return of 10.92%, sits alongside a much stronger picture over time. The 1 year total shareholder return is 30%, and the 3 year total shareholder return is above 7x. If you are...

In March 2026, Dynatrace, Inc. announced an expanded technology alliance with Postman, making its Model Context Protocol Server available via the Postman API Network so developers can access real-time observability and production context directly inside Postman’s AI-powered Agent Mode workflows. This integration allows Postman users to correlate API behavior with live production telemetry and automate troubleshooting in natural language without leaving their development environment,...

Beam Therapeutics (BEAM) shares are in focus after the company reported updated Phase 1/2 data for its AATD candidate BEAM-302, selected 60 mg as the preferred dose, and outlined plans for an accelerated approval path. See our latest analysis for Beam Therapeutics. Despite the BEAM-302 update, Beam Therapeutics’ shares have lost ground in the short term, with a 30 day share price return of 13.19% and a 90 day share price return of 14.89%. However, the 1 year total shareholder return remains...

How TAL Education Group stock has been performing recently TAL Education Group (NYSE:TAL) has seen mixed share performance recently, with a 0.9% gain over the past month, a similar rise over the past 3 months, and a negative 15.2% total return over the past year. Over longer horizons, the picture is very different. The 3 year total return is very large at around 7x, while the 5 year total return shows a 79.3% decline, underlining how timing has mattered for investors. Year to date, the stock...

Ecosuite announced that it has been selected by the District of Columbia Public Service Commission, alongside partner Ecogy Energy and with support from Exelon unit Pepco, for a 5‑year pilot to test how rooftop solar, battery storage and EV charging can be managed to improve local grid efficiency and reliability. This pilot puts Exelon, through Pepco, at the center of experimenting with customer‑sited energy resources that could influence how future distribution systems are planned and...

Wondering whether Prosperity Bancshares at around US$66 is offering good value today, or if the price already reflects its strengths? This article breaks down what the numbers are really saying about the stock. The share price is around US$66.41 after a recent 2.9% gain over the last 7 days, set against a 9.7% decline over 30 days and a 4.6% decline year to date and over 1 year, with a 3 year return of 18.6% and 5 year return of 2.8%. Recent coverage has focused on how Prosperity Bancshares...

Earlier this month, Anthropic announced that its Claude AI assistant can autonomously control computers, triggering concerns that value could shift from traditional application software toward the intelligence layer and put pressure on established providers like AppLovin in advertising technology. At the same time, AppLovin has been emphasizing the role of its first-party data and Axon 2.0 machine learning stack, highlighting how proprietary AI capabilities may influence its resilience as...

Upcoming Q1 earnings and shifting expectations Wells Fargo (WFC) heads into its Q1 2026 earnings report with analysts expecting profit of $1.56 per share, while at least one major brokerage has recently trimmed assumptions around net interest income and buybacks. See our latest analysis for Wells Fargo. At a share price of US$79.61, Wells Fargo has seen a 1-day share price return of 1.70% and 7-day share price return of 4.43%, although its 30-day and year to date share price returns are...

Alignment Healthcare CEO John E. Kao has arranged the indirect sale of 118,000 shares in NasdaqGS:ALHC under a preplanned trading program. The transaction is part of a trading plan that schedules sales in advance, rather than a one off discretionary move. Kao retains a substantial shareholding after the sale, keeping significant exposure to the company. For investors watching NasdaqGS:ALHC, this insider activity comes at a time when the stock trades at $17.42, with a 3 year return of 181.4%...

Stock performance snapshot Eli Lilly (LLY) has seen its share price retreat recently, with a 1 day return of 0.8%, a 1 week move of 2.9%, and a month performance of 10.5% in the red. Over the past 3 months, the stock is down 16.2%, with the year to date return at 16.4% lower. Even so, the 1 year total return sits at 6.7%, and the 3 year and 5 year total returns are very large multiples of the starting value. See our latest analysis for Eli Lilly. The recent 30 day share price return of 10.6%...

On March 18, 2026, Core Scientific, Inc. amended its delayed-draw bridge credit agreement, doubling total term loan commitments to US$1.00 billion and drawing the additional US$500.00 million to fund data center infrastructure, equipment, land, and energy procurement. This sizeable, fully drawn facility backed by Morgan Stanley and JPMorgan underscores lenders’ confidence in Core Scientific’s expansion plans and capital-intensive AI and high-performance computing ambitions. Next, we’ll...

If you are wondering whether Nelnet's current share price still offers value or if most of the opportunity is already priced in, this article will help you frame that question clearly. With the stock at US$129.60 and returns of 1.2% over 7 days, 0.5% year to date, and 16.9% over 1 year, recent performance provides a useful backdrop before looking at what the business might be worth. Recent news coverage about Nelnet has focused on its role as a diversified financial services company and how...

General Motors (NYSE:GM) has begun supervised public road testing of its next generation hands free, eyes off automated driving system on highways in California and Michigan. More than 200 GM vehicles are running the technology in live traffic as part of this test phase. GM plans a commercial rollout of the system on the 2028 Cadillac Escalade IQ, signaling its intent to bring higher automation levels to a flagship model. For investors, this move sits at the intersection of GM's core auto...

VinFast Auto (NasdaqGS:VFS) is back in focus after recent analyst meetings highlighted its emphasis on long-term expansion, ecosystem buildout around charging and ride-hailing, and the backdrop of strong reported electric vehicle delivery figures. See our latest analysis for VinFast Auto. The recent analyst meetings and strong delivery updates have come against a weaker trading backdrop, with a 90 day share price return of 14.37% decline and a 3 year total shareholder return of 70.81%...

Wondering whether Applied Optoelectronics at around US$113.90 is still offering value or has already priced in much of its story? This article walks through what the current valuation signals are really saying. The share price has recently been volatile, with returns of 31.9% over 7 days, 120.4% over 30 days, 187.6% year to date, 423.2% over 1 year and a very large gain over 3 years and 5 years based on the data provided. Recent coverage has focused on these sharp moves in the share price...

Stock performance snapshot and business profile Globus Medical (GMED) is on investors’ radar after a recent pullback, with the stock showing a 1-day return of a 1.10% decline and a past month return of a 4.79% decline. Over the past 3 months, Globus Medical has recorded a 2.47% decline, while the 1-year total return stands at 12.55%. Year to date, the stock is down 1.20%, giving investors mixed signals on short-term sentiment. The company has a market value of about US$11.80b and focuses on...

In recent weeks, Lakeland Financial Corporation director M. Scott Welch executed three open‑market purchases of LKFN common stock between February 27 and March 12, 2026, marking his first meaningful increase in beneficial ownership since March 2025. This cluster of insider buying stands out as a clear signal that a key board member is willing to commit additional personal capital amid sector uncertainty. We’ll examine how this recent insider buying flurry by Director M. Scott Welch shapes...

If you are wondering whether Ocugen's current share price still makes sense after a strong run, the key question is how that price lines up with the underlying value of the business. Ocugen shares, which last closed at US$1.92, have had a mixed but attention grabbing run, with a 21.6% decline over the last 7 days, a 20.0% gain over 30 days, 39.1% year to date, 168.6% over 1 year and 131.3% over 3 years, set against a 71.6% loss over 5 years. Recent news coverage has focused on Ocugen's...